Top Stories Tuesday, January 31, 2017 It’s been long known that President Donald Trump wanted to enact a federal hiring freeze and allow cuts by attrition, but lawmakers have sent a letter to the White House urging Trump to come clean on what this means for the agency. Tuesday, January 31, 2017 Seres Therapeutics has plotted a path forward for its Clostridium difficile infection program after digging into the data to learn where it went wrong in phase 2. The analysis picked out suboptimal doses and misdiagnoses as potential causes of the phase 2 flop, giving Seres the encouragement to push ahead with a follow-up trial despite the weak data. Tuesday, January 31, 2017 Astellas has licensed a drug that could provide an alternative to surgery for tympanic membrane perforation (TMP)—commonly known as a ruptured eardrum—developed by California's Auration Biotech. Tuesday, January 31, 2017 Heptares Therapeutics has teamed up with the University of Cambridge to discover molecules that modulate a cardiovascular target. The project builds on work at Cambridge to understand the role apelin receptors play in cardiovascular conditions including ischemic heart disease and discover a selective antagonist of the target. Tuesday, January 31, 2017 During its financials posted today, Pfizer quietly updated its pipeline showing that it has dropped three candidates from its testing programs, but as always, details were thin on the ground. Monday, January 30, 2017 Chemotherapy often causes infertility in young women because the drugs are designed to damage all rapidly growing cells, including those in ovarian follicles. Now researchers from Massachusetts General Hospital believe they’ve hit upon a method for protecting ovaries from the damaging effects of chemo. Friday, January 20, 2017 After an unusually slow year for new drug approvals—the FDA greenlighted just 22 meds in 2016—it remains to be seen whether drugmakers can do much better in 2017. One thing’s for sure, though: No matter what total the industry tallies up this year, the crop will bring some would-be blockbusters and market disrupters. Tuesday, January 31, 2017 Pharma has been called to the White House. Industry leaders will meet with President Donald Trump Tuesday morning. Eli Lilly CEO David Ricks, PhRMA chief Steven Ubl and Novartis CEO Joe Jimenez, the group's chairman-elect, are set to attend. | This week's sponsor is Destination Medical Center. | |  | Destination Medical Center (DMC) is a 20-year, $5.6 billion economic development plan set to transform Rochester, MN. DMC and Mayo Clinic are accelerating new advancements in life science research, medical technology, patient care, and education. |
| | | Abilita Bio says it has teed up another collaboration agreement with a "major pharma partner," but is not revealing who, which will use its EMP membrane protein evolution platform. Release Indivumed has signed a pact with Regeneron to provide it with cancer tissue samples for its research. Statement AbCheck has hit its first clinical milestone in its antibody discovery deal with Lilly after starting enrollment for a phase 1 test. Release | |
|
Resources Sponsored By: Veeva Learn over a dozen best practices for deploying a global content system. Read Whitepaper. Sponsored By: Veeva Gartner provides insightful research on preparing for IDMP compliance. Read Whitepaper. Sponsored By: Veeva Learn How to Create a Unified RIM Environment for IDMP. Find out. Sponsored By: Veeva The largest survey of TMF owners reveals drivers and trends in improving inspection readiness and shortening trial time. Sponsored By: Salesforce Learn how the healthcare and life science industry is using agile application development to drive innovation and accelerate their business with the Salesforce Platform. Presented by: Patheon Can you avoid a risky trial-and-error approach to find the right path for your poorly soluble molecule by utilizing a CDMO? Download this complimentary Whitepaper to learn more! | 
